Ten year experience with induction therapy in locally advanced non-small cell lung cancer (NSCLC): Is clinical re-staging predictive of pathological staging?

European Journal of Cardio-thoracic Surgery

Volumn 19, Issue 6, 2001, Pages 894-898

  Margaritora, Stefano ^a   Cesario, Alfredo ^a   Galetta, Domenico ^a   D'Andrilli, Antonio ^a   Macis, Giuseppe ^b   Mantini, Giovanna ^b   Trodella, Lucio ^b   Granone, Pierluigi ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Clinical restaging; Clinical staging; Induction therapy; Non small cell lung cancer; Pathological staging

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUOROURACIL; GEMCITABINE;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MEDIASTINOSCOPY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; THORACOSCOPY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT;

EID: 0034987080     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1010-7940(01)00697-2     Document Type: Article

References (21)

1. Revisions in the international system for staging lung cancer
2. Concurrent radiochemotherapy for N2 NSCLC. Interim analysis
3. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications
4. Docetaxel (Taxotere) in the neo-adjuvant setting in non small cell lung cancer
5. Role of multimodality treatment for lung cancer
6. Multimodality therapy for non small cell lung cancer
7. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer
8. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer
9. Randomized trial of neoadjuvant therapy for lung cancer: interim analysis
10. Phase III trial of neo-adjuvant chemotherapy (NCT) in resectable stage I (except T1N0), II, Iia non-small cell lung cancer (NSCLC): The French experience
11. Phase II trial of induction high-dose chemotherapy followed by surgical resection and radiation therapy for patients with marginally resectable non-small cell carcinoma of the lung
12. Multimodality therapy of patients with stage IIIa N2 non small cell lung cancer. Impact of pre-operative chemotherapy on resectability and downstaging
13. Assessment of preoperative accelerated radiotherapy and chemotherapy in stage IIIa (N2) non small cell lung cancer
14. Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIa non small cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study
15. Resection of stage III non small cell lung cancer following induction therapy
16. The role of induction therapy (neoadjuvant) chemotherapy in stage IIIa NSCLC
17. Pre-operative chemotherapy and irradiation for stage III non small cell lung cancer
18. Pilot study of neoadjuvant ifosfamide, cisplatin and etoposide in locally advanced non small cell lung cancer
19. Induction chemotherapy with mitomicin, vindesine and cisplatin for stage III unresectable non small cell lung cancer: results of the Toronto phase II trial
20. Preoperative chemotherapy and radiation therapy for stage IIIa carcinoma of the lung
21. Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan Kettering experience with 136 patients